Access to cancer medicines in Australia

Past investment in cancer care has resulted in the country being a world leader in cancer control, but disease incidence is projected to grow significantly over the next 20 years.

In this report for the Medicines Australia Oncology Industry Taskforce, Deloitte Access Economics has assessed the disease patterns and economics of cancer in Australia and internationally, and canvassed the opinions of various stakeholders on issues pertaining to patient access to cancer medicines.